Healthcare - Biotechnology - NASDAQ - US
$ 13.83
-3.49 %
$ 200 M
Market Cap
0.12
P/E
BALANCE SHEET
308 M
ASSETS
264 M
LIABILITIES
43.5 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Inhibrx Biosciences, Inc.
| Current Assets | 295 M |
| Cash & Short-Term Investments | 278 M |
| Receivables | 778 K |
| Other Current Assets | 16.7 M |
| Non-Current Assets | 12.5 M |
| Long-Term Investments | 0 |
| PP&E | 9.37 M |
| Other Non-Current Assets | 3.16 M |
| Current Liabilities | 56.3 M |
| Accounts Payable | 8.31 M |
| Short-Term Debt | 4.13 M |
| Other Current Liabilities | 43.9 M |
| Non-Current Liabilities | 208 M |
| Long-Term Debt | 208 M |
| Other Non-Current Liabilities | 0 |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Cash & Cash Equivalents | 277.9 | 273.9 | 131.3 | 128.7 | 11.5 | 2.1 | 13.5 | 20.0 |
| Short Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0.8 | 0.3 | 0.9 | 0.6 | 0.4 | 0.7 | 0.7 | 0 |
| Inventory | (11.6) | (0.3) | (0.9) | (129.3) | 3.2 | 2.3 | 1.0 | 0 |
| Other Current Assets | 28.2 | 5.5 | 7.8 | 132.2 | 0.4 | 0.6 | 0.3 | 0.4 |
| Total Current Assets | 295.4 | 280.5 | 139.1 | 132.2 | 15.6 | 5.7 | 15.4 | 20.4 |
| PP&E | 9.4 | 7.2 | 9.5 | 11.3 | 10.7 | 2.6 | 1.8 | 0.9 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Long Term Assets | 3.2 | 3.2 | 1.8 | 0.2 | 0.2 | 1.7 | 0 | 1 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Assets | 307.9 | 290.9 | 150.4 | 143.7 | 26.5 | 10.0 | 17.2 | 21.3 |
| LIABILITIES | ||||||||
| Accounts Payable | 8.3 | 4.3 | 9.1 | 13.5 | 3.1 | 6.5 | 0.8 | 0.2 |
| Short Term Debt | 4.1 | 3.7 | 1.7 | 1.5 | 4.7 | 5.9 | 5.2 | 4.3 |
| Other Current Liabilities | 43.9 | 19.3 | 9.6 | 13.4 | 4.8 | 2.1 | 0.4 | 0.9 |
| Total Current Liabilities | 56.3 | 27.6 | 22.5 | 31.4 | 20.6 | 16.2 | 8.9 | 5.3 |
| Long Term Debt | 208.1 | 205.2 | 70.5 | 36.0 | 37.1 | 3.6 | 9.5 | 14.7 |
| Deferred Tax Income | 0 | 0 | (0.1) | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 5.1 | 0.2 | 61.4 | 47.9 | 21.3 | 92 K |
| Total Liabilities | 264.4 | 232.8 | 98.1 | 68.3 | 120.1 | 67.6 | 39.7 | 20.0 |
| EQUITY | ||||||||
| Common Stock | 5 K | 4 K | 4 K | 4 K | 2 K | 3 K | 0 | 0 |
| Retained Earnings | (613.7) | (372.4) | (227.1) | (145.4) | (69.3) | (17.9) | (28.8) | (9.2) |
| Other Accumulative Comprehensive Income/Loss | 0 | 0 | (150.4) | (143.7) | (59.5) | (1.7) | (1.0) | 0 |
| Total Equity | 43.5 | 58.1 | 52.4 | 75.5 | (93.6) | (57.6) | (22.4) | 1.2 |
| Total Liabilities and Equity | 307.9 | 290.9 | 150.4 | 143.7 | 26.5 | 10.0 | 17.2 | 21.3 |
| SHARES OUTSTANDING | ||||||||
| Common Shares Outstanding | 47.1 | 40.1 | 38.0 | 25.3 | 36.6 | 27.1 | 28.8 | 36.6 |